Investigating paraoxonase-1 gene Q192R and L55M polymorphism in patients with renal cell cancer.

Increased oxidative stress can help promote carcinogenesis, including development of renal cell carcinoma. The enzyme protects low-density lipoproteins from oxidation and can be a factor in this process. PON1 Q192R and L55M paraoxonase gene polymorphisms were assessed in 60 renal cell carcinoma patients and 60 healthy controls. Genotypes were examined by PCR; the restriction enzyme AlwI was used to examine the Q192R polymorphism and Hsp92II for the L55M polymorphism. Significant differences in the PON1 Q192R polymorphism were found between patients and controls. The Q allele was more frequent in the patient group than in controls, while the R allele was more frequent in the control group. No significant differences were found in the L55M polymorphism. Additionally, there were no significant differences in L and M allele frequencies. We conclude that the R allele may protect against renal cell carcinoma.

[1]  T. Simić,et al.  Altered antioxidant capacity in human renal cell carcinoma: role of glutathione associated enzymes. , 2008, Urologic oncology.

[2]  S. Koca,et al.  Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population , 2007, BMC Cancer.

[3]  M. Gago-Domínguez,et al.  Lipid peroxidation and renal cell carcinoma: further supportive evidence and new mechanistic insights. , 2006, Free radical biology & medicine.

[4]  Luigi Mearini,et al.  Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer , 2005, The Prostate.

[5]  T. Wobbes,et al.  No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. , 2005, Anticancer research.

[6]  M. Akçay,et al.  Serum paraoxonase levels in gastric cancer. , 2003, Hepato-gastroenterology.

[7]  M. Akçay,et al.  Serum paraoxonase levels in pancreatic cancer. , 2003, Hepato-gastroenterology.

[8]  Jian-Min Yuan,et al.  Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States) , 2002, Cancer Causes & Control.

[9]  P. Durrington,et al.  Paraoxonase and Atherosclerosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[10]  J L Warren,et al.  Rising incidence of renal cell cancer in the United States. , 1999, JAMA.

[11]  D. Bonnefont-Rousselot,et al.  High Density Lipoproteins (HDL) and the Oxidative Hypothesis of Atherosclerosis , 1999, Clinical chemistry and laboratory medicine.

[12]  S. Campbell,et al.  Advances in angiogenesis research: relevance to urological oncology. , 1997, The Journal of urology.

[13]  P. Durrington,et al.  Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon , 1997, British journal of pharmacology.

[14]  B. Delahunt,et al.  Classification of renal cell carcinoma , 1997, Cancer.

[15]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[16]  R. Hegele,et al.  Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins , 1996, Current opinion in lipidology.

[17]  M. Benson,et al.  The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. , 1995, The Journal of urology.

[18]  R. Humbert,et al.  Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. , 1991, Biochemistry.

[19]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[20]  D. Evans,et al.  Genetic polymorphism and interethnic variability of plasma paroxonase activity. , 1976, Journal of medical genetics.

[21]  T. Wobbes,et al.  No Association Between Genetic Polymorphisms in NAD ( P ) H Oxidase p 22 phox and Paraoxonase 1 and Colorectal Cancer Risk , 2009 .

[22]  P. Tosi,et al.  Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. , 2001, International journal of cancer.

[23]  R. Bast,et al.  Principles of Cancer Pathology , 2000 .

[24]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[25]  S. Clifford,et al.  Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. , 1998, Genes, chromosomes & cancer.

[26]  J. Eble,et al.  CLASSIFICATION OF RENAL CELL CARCINOMA: WORK GROUP , 1997 .

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.